NYSE$NSPR
InspireMD Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
InspireMD's Q4 2020 results were negatively impacted by a litigation settlement and COVID-19, leading to decreased revenue and gross profit, but the company made progress on strategic initiatives and improved its cash position through public offerings.
InspireMD reported a significant decrease in revenue for Q4 2020, primarily due to a litigation settlement and the impact of COVID-19 on procedure volumes. Gross profit also declined significantly. However, the company highlighted progress in strategic initiatives, including IDE approval in the US and expansion in Latin America and China, and improved its cash position through public offerings.
- Revenue decreased by 84.4% to $158,000 due to a litigation settlement and COVID-19 impacts.
- Gross profit decreased by 250.6% to negative $390,000, primarily due to the settlement.
- Operating expenses increased by 20.4% to $3,328,000 due to investments in infrastructure and personnel.
- Net loss totaled $3,853,000, or $0.10 per share, compared to a net loss of $2,557,000, or $0.57 per share, for the same period in 2019.
Headline financials
Revenue & EPS history
InspireMD · Revenue · Quarterly
$158K
Revenue by segment
InspireMD · $689K total across 1 segment · Q4 2020
- CGuard EPS$689K-25.2%100.0%
Forward guidance
The company did not provide specific financial guidance, but expressed optimism for 2021, citing foundational achievements in 2020, including IDE approval, market expansion, and improved financial position.
Tailwinds
- FDA approval of IDE application for CGuard™ EPS pivotal study in the United States.
- Expansion of market presence with CGuard registration and distribution in Brazil.
- Investment and distribution agreement to enter mainland China.
- Applying for regulatory and reimbursement approvals in new markets such as France, Taiwan and Korea.
- Improved cash position after completing multiple public offerings.
Headwinds
- Revenue was negatively impacted by the settlement of litigation with a former distributor.
- COVID-19 pandemic curtailed the ability to grow revenue.
- Postponement of procedures with CGuard EPS due to hospitals shifting resources to patients affected by COVID-19.
- Decrease in sales volume of MGuard Prime EPS due to the impact of COVID-19.
- Gross margin decreased due to the settlement with a former distributor.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2020
-3.7%
Avg return
Earnings day
-7.1%
Avg return
5 days after
-12.5%
Avg return
30 days after
32%
19 / 60 earnings
Positive
+15.4%
Q4 2014
Best reaction
-26.3%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.7% | +0.0% | — | |
| Q4 2025 | +0.0% | -2.8% | -24.6% | |
| Q3 2025 | -7.0% | -21.0% | -16.2% | |
| Q1 2025 | +0.0% | -9.2% | -3.8% | |
| Q4 2024 | +0.7% | +0.4% | -8.2% | |
| Q3 2024 | +2.0% | +2.8% | +25.6% | |
| Q2 2024 | -3.4% | -3.4% | -7.4% | |
| Q1 2024 | -4.2% | -4.2% | +8.3% | |
| Q4 2023 | +0.4% | -3.0% | -12.9% | |
| Q3 2023 | -6.0% | -9.0% | -26.1% | |
| Q2 2023 | +0.0% | +3.5% | +11.9% | |
| Q1 2023 | -4.3% | -2.2% | +11.4% | |
| Q4 2022 | -1.7% | -6.1% | -9.6% | |
| Q3 2022 | -13.9% | -22.2% | +5.6% | |
| Q2 2022 | -6.3% | -5.9% | -15.1% | |
| Q1 2022 | -3.9% | +1.0% | +1.9% | |
| Q4 2021 | +4.6% | -4.6% | +19.8% | |
| Q3 2021 | -1.4% | -3.4% | -14.9% | |
| Q2 2021 | -2.5% | -4.8% | +7.8% | |
| Q1 2021 | +0.6% | -3.2% | +23.6% | |
| Q4 2020 | -11.4% | -4.9% | -20.5% | |
| Q3 2020 | +2.9% | +0.0% | +0.0% | |
| Q2 2020 | -2.1% | -2.1% | -27.7% | |
| Q1 2020 | +13.5% | +6.8% | -24.3% | |
| Q4 2019 | -22.0% | -35.4% | -18.3% | |
| Q3 2019 | -26.3% | -33.8% | -31.6% | |
| Q2 2019 | -19.9% | -18.0% | -11.4% | |
| Q1 2019 | -19.4% | -24.3% | -14.4% | |
| Q4 2018 | -10.0% | -12.5% | -46.6% | |
| Q3 2018 | -4.2% | -8.3% | -20.8% | |
| Q2 2018 | +4.8% | +4.8% | -9.5% | |
| Q1 2018 | +7.3% | -2.4% | -7.3% | |
| Q4 2017 | -1.0% | -0.8% | -41.2% | |
| Q3 2017 | +0.0% | +2.6% | -64.1% | |
| Q2 2017 | -6.3% | -16.7% | -33.3% | |
| Q1 2017 | +0.0% | -7.9% | -12.7% | |
| Q4 2016 | -9.0% | -14.5% | -59.0% | |
| Q3 2016 | -4.1% | +2.4% | +22.9% | |
| Q2 2016 | -10.5% | -15.8% | -31.6% | |
| Q1 2016 | -14.3% | — | — | |
| Q4 2015 | +2.0% | — | — | |
| Q3 2015 | -15.8% | — | — | |
| Q2 2015 | -25.0% | — | — | |
| Q1 2015 | -11.5% | — | — | |
| Q4 2014 | +15.4% | — | — | |
| Q3 2014 | -3.3% | — | — | |
| Q2 2014 | +2.1% | — | — | |
| Q1 2014 | +1.8% | — | — | |
| Q4 2013 | +2.0% | — | — | |
| Q3 2013 | -3.1% | — | — | |
| Q2 2013 | -0.9% | — | — | |
| Q1 2013 | -6.0% | — | — | |
| Q4 2012 | -8.6% | — | — | |
| Q3 2012 | +1.4% | — | — | |
| Q2 2012 | +2.1% | — | — | |
| Q1 2012 | -16.8% | — | — | |
| Q4 2011 | +9.7% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +7.7% | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro